肽类抗生素市场机会、成长动力、产业趋势分析及2025-2034年预测

2024 年全球胜肽类抗生素市场价值为 52 亿美元，预计 2025 年至 2034 年的复合年增长率为 5%。由于抗菌素抗药性 (AMR) 威胁不断升级，导致对先进抗生素解决方案的需求迫切，市场正在经历显着扩张。随着细菌感染对传统治疗的抵抗力越来越强，胜肽类抗生素正成为重要的替代品。这些专门的抗生素，包括多粘菌素和短桿菌肽，对多重抗药性 (MDR) 微生物表现出强大的活性，使其成为对抗抗药性感染不可或缺的药物。

随着世界各地的医疗保健系统努力应对日益增多的抗生素抗药性病例，製药公司正致力于研发工作，将创新的胜肽类抗生素推向市场。医院获得性感染 (HAI) 和血液感染的日益普及进一步加剧了对有效治疗方案的需求，从而推动了对该领域的投资。

随着製药业的主要参与者合作开发可提高疗效并最大限度降低抗药性风险的新型药物配方，基于胜肽的新型治疗方法的管道正在不断扩大。此外，政府应对抗生素抗药性的倡议不断增加以及对抗生素研究的资助在塑造市场成长轨迹方面发挥着至关重要的作用。人们越来越重视具有针对性作用且副作用最小的下一代抗生素，这推动了基于胜肽的解决方案的开发，这些解决方案对于治疗不再对传统疗法有反应的严重细菌感染特别有用。

市场主要分为核醣体合成胜肽抗生素和非核醣体合成胜肽抗生素。 2024 年，非核醣体合成胜肽抗生素领域占据市场主导地位，估值达 14 亿美元。这些抗生素透过非核醣体胜肽合成酶（NRPS）产生，具有结构多样性和增强的抗酶降解能力。它们能够结合非蛋白质氨基酸，从而具有优异的抗菌性能，能够更有效地对抗抗药性极强的病原体。因此，非核醣体合成胜肽抗生素仍然是医疗保健提供者和研究人员寻求更持久、更广谱的抗菌剂的首选。

肽类抗生素市场按应用细分，重点关注领域包括皮肤感染、医院获得性细菌性肺炎、血液感染和其他细菌性疾病。 2024 年，皮肤感染成为主要领域，占 33.7% 的市场。蜂窝性组织炎、脓疱病和糖尿病足溃疡等疾病的盛行率不断上升，加上慢性伤口和术后感染的激增，推动了对这些有针对性的抗生素的需求。肽类抗生素提供了更精确的治疗方法，同时降低了全身毒性，对于需要长期抗菌治疗的潜在健康问题患者来说非常有效。

北美仍是胜肽类抗生素的主要区域市场，2023 年占 40.6%。尤其是美国，在强大的製药研究生态系统、完善的监管框架和大量医疗保健支出的支持下，继续推动该领域的成长。美国领先的生物技术和製药公司的存在促进了抗生素开发的持续创新。随着抗菌药物抗药性病例的增加，国内对新型胜肽类抗生素的需求将会增加，以提供更有针对性、更有效的治疗选择，降低抗生素抗药性的风险。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 多重抗药性（MDR）细菌的盛行率不断上升
    • 急性和慢性传染病发生率不断上升
    • 肽合成技术步骤
  • 产业陷阱与挑战
    • 生产成本高
    • 口服生物利用度有限
• 成长潜力分析
• 监管格局
• 管道分析
• 未来市场趋势
• 波特的分析
• PESTEL 分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按类型，2021 年至 2034 年

• 主要趋势
• 核醣体合成胜肽抗生素
• 非核醣体合成胜肽类抗生素

第六章：市场估计与预测：按适应症，2021 年至 2034 年

• 主要趋势
• 皮肤感染
• 本院获得性细菌性肺炎和呼吸器相关性细菌性肺炎（HABP/VABP）
• 血流感染
• 其他适应症

第七章：市场估计与预测：依管理路线，2021 年至 2034 年

• 主要趋势
• 注射剂
• 口服
• 主题
• 其他给药途径

第八章：市场估计与预测：按配销通路，2021 年至 2034 年

• 主要趋势
• 医院药房
• 零售药局
• 网路药局

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• AbbVie
• ANI Pharmaceuticals
• Cumberland Pharmaceuticals
• Eli Lilly and Company
• GSK plc
• JHP Pharmaceuticals
• Merck
• Monarch Pharmachem
• Melinta Therapeutics
• NPS Pharmaceuticals
• Pfizer
• Sanofi
• Sandoz
• Teva Pharmaceuticals
• The Menarini Group
• Xellia Pharmaceuticals

The Global Peptide Antibiotics Market was valued at USD 5.2 billion in 2024 and is projected to grow at a CAGR of 5% from 2025 to 2034. The market is experiencing significant expansion due to the escalating threat of antimicrobial resistance (AMR), which has led to an urgent demand for advanced antibiotic solutions. With bacterial infections becoming increasingly resistant to conventional treatments, peptide antibiotics are emerging as a crucial alternative. These specialized antibiotics, including polymyxins and gramicidin, exhibit potent activity against multidrug-resistant (MDR) microbes, making them indispensable in combating resistant infections.

As healthcare systems worldwide grapple with rising cases of antibiotic resistance, pharmaceutical companies are focusing on research and development efforts to bring innovative peptide antibiotics to the market. The growing prevalence of hospital-acquired infections (HAIs) and bloodstream infections has further intensified the need for effective treatment options, driving investments in this segment.

The pipeline for new peptide-based treatments is expanding as major players in the pharmaceutical industry collaborate on novel drug formulations that enhance efficacy and minimize resistance risks. Additionally, increasing government initiatives to tackle AMR and funding for antibiotic research are playing a crucial role in shaping the growth trajectory of the market. The emphasis on next-generation antibiotics that provide targeted action with minimal side effects is fueling the development of peptide-based solutions, which are particularly useful in treating severe bacterial infections that no longer respond to traditional therapies.

The market is primarily categorized into ribosomal and non-ribosomal synthesized peptide antibiotics. In 2024, the non-ribosomal synthesized peptide antibiotics segment dominated the market, holding a valuation of USD 1.4 billion. These antibiotics, produced through non-ribosomal peptide synthetases (NRPSs), offer structural diversity and enhanced resistance to enzymatic degradation. Their ability to incorporate non-proteinogenic amino acids gives them superior antimicrobial properties, making them more effective in tackling highly resistant pathogens. As a result, non-ribosomal synthesized peptide antibiotics continue to be the preferred choice among healthcare providers and researchers striving for more durable and broad-spectrum antibacterial agents.

The peptide antibiotics market is segmented by application, with key focus areas including skin infections, hospital-acquired bacterial pneumonia, bloodstream infections, and other bacterial conditions. Skin infections emerged as the leading segment in 2024, accounting for a 33.7% share of the market. The increasing prevalence of conditions such as cellulitis, impetigo, and diabetic foot ulcers, along with a surge in chronic wounds and post-surgical infections, is fueling demand for these targeted antibiotics. Peptide antibiotics offer a more precise treatment approach with reduced systemic toxicity, making them highly effective for patients with underlying health conditions requiring prolonged antibacterial therapy.

North America remained the dominant regional market for peptide antibiotics, accounting for a 40.6% share in 2023. The United States, in particular, continues to drive growth in this sector, supported by a strong pharmaceutical research ecosystem, a well-established regulatory framework, and substantial healthcare spending. The presence of leading biotechnology and pharmaceutical firms in the U.S. fosters continuous innovation in antibiotic development. With the rise of AMR cases, the demand for new peptide antibiotics in the country is set to increase, providing more targeted and efficient treatment options that reduce the risk of antibiotic resistance.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of multi-drug resistant (MDR) bacteria
    • 3.2.1.2 Increasing incidence of acute and chronic infectious diseases
    • 3.2.1.3 Technological advancements in peptide synthesis
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High production costs
    • 3.2.2.2 Limited oral bioavailability
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter’s analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Ribosomal synthesized peptide antibiotics
• 5.3 Non-ribosomal synthesized peptide antibiotics

Chapter 6 Market Estimates and Forecast, By Indication, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Skin infection
• 6.3 Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP)
• 6.4 Blood stream infections
• 6.5 Other indications

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Injectable
• 7.3 Oral
• 7.4 Topical
• 7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospital pharmacies
• 8.3 Retail pharmacies
• 8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 AbbVie
• 10.2 ANI Pharmaceuticals
• 10.3 Cumberland Pharmaceuticals
• 10.4 Eli Lilly and Company
• 10.5 GSK plc
• 10.6 JHP Pharmaceuticals
• 10.7 Merck
• 10.8 Monarch Pharmachem
• 10.9 Melinta Therapeutics
• 10.10 NPS Pharmaceuticals
• 10.11 Pfizer
• 10.12 Sanofi
• 10.13 Sandoz
• 10.14 Teva Pharmaceuticals
• 10.15 The Menarini Group
• 10.16 Xellia Pharmaceuticals